Dimethyl 3-(cyclohexylcarbamoyl)-5-methylfuran-2,4-dicarboxylate | 959420-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: Dimethyl 3-(cyclohexylcarbamoyl)-5-methylfuran-2,4-dicarboxylate
• CAS: 959420-02-1
• 化学式: C₁₆H₂₁NO₆
• 分子量: 323.346
• InChiKey: HYEBZOCEHMFYRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  94.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  Methyl 4-(cyclohexylamino)-4-oxobut-2-ynoate 、 3-(Acetyl-methyl-amino)-2-diazo-3-oxo-propionic acid methyl ester 在 rhodium perfluorobutyramidate 作用下， 以 甲苯 为溶剂， 以16%的产率得到Dimethyl 4-(cyclohexylcarbamoyl)-5-methylfuran-2,3-dicarboxylate
  参考文献：
  名称：

  Compounds and methods for treating tumors, cancer and hyperproliferative diseases

  摘要：

  本发明涉及新化合物、药物组合物和治疗肿瘤、癌症和高增殖性疾病的方法，包括银屑病、生殖器疣和高增殖性细胞生长疾病，包括高增殖性角质细胞疾病，如角化症、鱼鳞病、角皮病或扁平苔藓病。这些化合物根据其化学结构描述如下：其中R1为H、OH、F、Cl、Br、I、C1-C6可选择取代的烷基或烯基基团、可选择取代的芳基团或a 基团；Ra为H、OH、C1-C10、可选择取代的烷基或烯基基团、可选择取代的O—(C1-C7烷基基团)或O-芳基团、可选择取代的胺基团，该胺基团可选择取代至少一个C1-C10烷基基团，该基团可选择取代，或者单一可选择取代的芳基团、联苯基团、(C1-C6)烷基芳基团、(C1-C6)烷基联苯基团、杂环芳基团、杂环基团、(C1-C6)烷基杂环芳基团或(C1-C6)烷基杂环基团；R2为a 基团；Rb为H、OH、C1-C10、可选择取代的烷基或烯基基团、可选择取代的O—(C1-C7烷基基团)或O-芳基团、可选择取代的胺基团，该胺基团可选择取代至少一个C1-C10烷基基团，该基团可选择取代，或者单一可选择取代的芳基团、联苯基团、(C1-C6)烷基芳基团、(C1-C6)烷基联苯基团、杂环芳基团、杂环基团、(C1-C6)烷基杂环芳基团或(C1-C6)烷基杂环基团；R3和R6各自独立地选择自H、OH、F、Cl、Br、I、C1-C6可选择取代的烷基或烯基基团、可选择取代的芳基团、碳酸酯、烷基碳酸酯、脲或烷基脲；R4为a 基团，其中Rb如上所述；和R5为a 基团，其中Rb如上所述，但至少其中之一的R1和R2或R4和R5含有Ra或Rb基团，该基团为可选择取代的胺基团，该胺基团可选择取代至少一个C1-C10烷基基团，该基团可选择取代，或者单一可选择取代的芳基团、联苯基团、(C1-C6)烷基芳基团、(C1-C6)烷基联苯基团、杂环芳基团、杂环基团、(C1-C6)烷基杂环芳基团或(C1-C6)烷基杂环基团；或其立体异构体、药用可接受的盐、溶剂化合物和多晶形式。

  公开号：

  US07304092B1

文献信息

• US7304092B1
  申请人：——

  公开号：US7304092B1

  公开（公告）日：2007-12-04
• Compounds and methods for treating tumors, cancer and hyperproliferative diseases
  申请人：Yale University

  公开号：US07304092B1

  公开（公告）日：2007-12-04

  The present invention relates to novel compounds, pharmaceutical compositions and methods for treating tumors, cancer and hyperproliferative diseases including psoriasis, genital warts and hyperproliferative cell growth diseases, including hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus. These compounds are described according to the chemical structure: where R1 is H, OH, F, Cl, Br, I, a C1-C6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group or a  group; Ra is a H, OH, C1-C10, optionally substituted alkyl or alkenyl group, an optionally substituted O—(C1-C7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C1-C10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C1-C6) alkylenearyl group, (C1-C6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C1-C6) alkylene heteroaryl group or (C1-C6) alkylene heterocyclic group; R2 is a  group; Rb is a H, OH, C1-C10, optionally substituted alkyl or alkenyl group, an optionally substituted O—(C1-C7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C1-C10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C1-C6) alkylenearyl group, (C1-C6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C1-C6) alkylene heteroaryl group or (C1-C6) alkylene heterocyclic group; R3 and R6 are each independently selected from H, OH, F, Cl, Br, I, a C1-C6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group, a carbamate, alkylene carbamate, urethane or alkylene urethane; R4 is a  group, wherein Rb is as described above; and R5 is a  group, wherein Rb is as described above, with the proviso that at least one of R1 and R2 or R4 and R5 contains an Ra or Rb group which is an amine group which is optionally substituted with at least one C1-C10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C1-C6) alkylenearyl group, (C1-C6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C1-C6) alkylene heteroaryl group or (C1-C6) alkylene heterocyclic group; or a stereoisomer, pharmaceutically acceptable salt, solvate, and polymorph thereof.

  本发明涉及新化合物、药物组合物和治疗肿瘤、癌症和高增殖性疾病的方法，包括银屑病、生殖器疣和高增殖性细胞生长疾病，包括高增殖性角质细胞疾病，如角化症、鱼鳞病、角皮病或扁平苔藓病。这些化合物根据其化学结构描述如下：其中R1为H、OH、F、Cl、Br、I、C1-C6可选择取代的烷基或烯基基团、可选择取代的芳基团或a 基团；Ra为H、OH、C1-C10、可选择取代的烷基或烯基基团、可选择取代的O—(C1-C7烷基基团)或O-芳基团、可选择取代的胺基团，该胺基团可选择取代至少一个C1-C10烷基基团，该基团可选择取代，或者单一可选择取代的芳基团、联苯基团、(C1-C6)烷基芳基团、(C1-C6)烷基联苯基团、杂环芳基团、杂环基团、(C1-C6)烷基杂环芳基团或(C1-C6)烷基杂环基团；R2为a 基团；Rb为H、OH、C1-C10、可选择取代的烷基或烯基基团、可选择取代的O—(C1-C7烷基基团)或O-芳基团、可选择取代的胺基团，该胺基团可选择取代至少一个C1-C10烷基基团，该基团可选择取代，或者单一可选择取代的芳基团、联苯基团、(C1-C6)烷基芳基团、(C1-C6)烷基联苯基团、杂环芳基团、杂环基团、(C1-C6)烷基杂环芳基团或(C1-C6)烷基杂环基团；R3和R6各自独立地选择自H、OH、F、Cl、Br、I、C1-C6可选择取代的烷基或烯基基团、可选择取代的芳基团、碳酸酯、烷基碳酸酯、脲或烷基脲；R4为a 基团，其中Rb如上所述；和R5为a 基团，其中Rb如上所述，但至少其中之一的R1和R2或R4和R5含有Ra或Rb基团，该基团为可选择取代的胺基团，该胺基团可选择取代至少一个C1-C10烷基基团，该基团可选择取代，或者单一可选择取代的芳基团、联苯基团、(C1-C6)烷基芳基团、(C1-C6)烷基联苯基团、杂环芳基团、杂环基团、(C1-C6)烷基杂环芳基团或(C1-C6)烷基杂环基团；或其立体异构体、药用可接受的盐、溶剂化合物和多晶形式。